Literature DB >> 21061399

Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations.

Marlies J Valstar1, Sanne Neijs, Hennie T Bruggenwirth, Renske Olmer, George J G Ruijter, Ron A Wevers, Otto P van Diggelen, Ben J Poorthuis, Dicky J Halley, Frits A Wijburg.   

Abstract

OBJECTIVE: Mucopolysaccharidosis (MPS) IIIA (Sanfilippo syndrome type A) is a lysosomal storage disorder caused by deficiency of the enzyme sulfamidase. Information on the natural course of MPS IIIA is scarce, but is much needed in view of emerging therapies.
METHODS: Clinical history and molecular defects of all 110 MPS IIIA patients identified by enzymatic studies in the Netherlands were collected and included in this study.
RESULTS: First clinical signs, mainly consisting of delayed speech development and behavioral problems, were noted between the ages of 1 and 6 years. Other symptoms included sleeping and hearing problems, recurrent upper airway infections, diarrhea, and epilepsy. The clinical course varied remarkably and could be correlated with the molecular defects. The frequent pathogenic mutations p.R245H, p.Q380R, p.S66W, and c.1080delC were associated with the classical severe phenotype. Patients compound heterozygous for the p.S298P mutation in combination with 1 of the mutations associated with the classical severe phenotype had a significantly longer preservation of psychomotor functions and a longer survival. Two patients homozygous for the p.S298P mutation, and 4 patients from 3 families heterozygous for 3 missense variants not reported previously (p.T421R, p.P180L, and p.L12Q), showed a remarkably attenuated phenotype.
INTERPRETATION: We report the natural history and mutational analysis in a large unbiased cohort of MPS IIIA patients. We demonstrate that the clinical spectrum of MPS IIIA is much broader than previously reported. A significant genotype-phenotype correlation was established in this cohort.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21061399     DOI: 10.1002/ana.22092

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  59 in total

1.  A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA.

Authors:  Elsa G Shapiro; Igor Nestrasil; Kathleen A Delaney; Kyle Rudser; Victor Kovac; Nitin Nair; Charles W Richard; Patrick Haslett; Chester B Whitley
Journal:  J Pediatr       Date:  2016-01-16       Impact factor: 4.406

2.  Growth in patients with mucopolysaccharidosis type III (Sanfilippo disease).

Authors:  J de Ruijter; L Broere; M F Mulder; A T van der Ploeg; M E Rubio-Gozalbo; S B Wortmann; G Visser; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2013-10-31       Impact factor: 4.982

Review 3.  Lysosomal storage disease overview.

Authors:  Angela Sun
Journal:  Ann Transl Med       Date:  2018-12

4.  A Novel Homozygous Missense Variant in the NAGA Gene with Extreme Intrafamilial Phenotypic Heterogeneity.

Authors:  Fedah E Mohamed; Mohammad Al Sorkhy; Mohammad A Ghattas; Nuha Al-Zaabi; Aisha Al-Shamsi; Taleb M Almansoori; Lihadh Al-Gazali; Osama Y Al-Dirbashi; Fatma Al-Jasmi; Bassam R Ali
Journal:  J Mol Neurosci       Date:  2019-08-29       Impact factor: 3.444

5.  Early Umbilical Cord Blood-Derived Stem Cell Transplantation Does Not Prevent Neurological Deterioration in Mucopolysaccharidosis Type III.

Authors:  Lindsey Welling; Jan Pieter Marchal; Peter van Hasselt; Ans T van der Ploeg; Frits A Wijburg; Jaap Jan Boelens
Journal:  JIMD Rep       Date:  2014-09-26

Review 6.  Glycan-based biomarkers for mucopolysaccharidoses.

Authors:  Roger Lawrence; Jillian R Brown; Fred Lorey; Patricia I Dickson; Brett E Crawford; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2013-07-29       Impact factor: 4.797

7.  Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.

Authors:  Barbara King; Neil Marshall; Helen Beard; Sofia Hassiotis; Paul J Trim; Marten F Snel; Tina Rozaklis; Robert D Jolly; John J Hopwood; Kim M Hemsley
Journal:  J Inherit Metab Dis       Date:  2014-11-25       Impact factor: 4.982

Review 8.  Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders.

Authors:  E M Cross; D J Hare
Journal:  J Inherit Metab Dis       Date:  2013-02-06       Impact factor: 4.982

9.  Heparan sulfate derived disaccharides in plasma and total urinary excretion of glycosaminoglycans correlate with disease severity in Sanfilippo disease.

Authors:  J de Ruijter; L Ijlst; W Kulik; H van Lenthe; T Wagemans; N van Vlies; F A Wijburg
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

10.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.